Lornoxicam

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C13H10ClN3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ER09126G7A, chemically known as 6-chloro-4-hydroxy-2-methyl-n-2-pyridyl-2h-thieno(2,3-e)-1,2-thiazine-3-carboxamide 1,1-dioxide but generally known as lornoxicam, which bears US NIH Compound Identifier 5282204. European Medicines Agency schedules Lornoxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08589MIG. The term LORNOXICAM is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, No. 3, 1989, List 29). World Health Organization schedules lornoxicam in its Anatomical Therapeutic Chemical (ATC) Classification. LORNOXICAM is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule lornoxicam under HS 29349990 and SITC 51579. As of Q4 2014, LORNOXICAM remains the US FDA Preferred Term for this commodity. Lornoxicam bears US NLM identifiers UMLS ID C0055477 and NCI Concept Code C72140. SMILES: CLC1SC2C(S(=O)(=O)N(/C(=C(/O)NC3NCCCC3)C2=O)C)C1.